Skip to main content
AAN.com
Article
February 1, 1997

Survival of patients with pathologically proven multiple system atrophy
A meta-analysis

February 1997 issue
48 (2) 384-393

Abstract

Article abstract-A systematic review of the neurologic literature identified 433 cases of pathologically proven multiple system atrophy over a 100-year period. Earlier case reports included patients younger in age with more frequent cerebellar involvement. Mean age of onset was 54.2 years (range 31 to 78) and survival was 6.2 years (range 0.5 to 24). Survival analysis showed a secular trend from a median duration of 4.9 years for publications between 1887 and 1970 to 6.8 years between 1991 and 1994. Older age of onset was associated with shorter survival; the hazard ratio for patients with onset after 60 years was 1.8 (95% CI 1.4 to 2.3) compared with patients between 31 and 49 years. Cerebellar features were associated with marginally increased survival (6.1 years versus 5.4 years; p = 0.04). There were no differences in survival according to gender, parkinsonian, or pyramidal features or whether the patient was classified as striatonigral degeneration or olivopontocerebellar atrophy type. These results demonstrate the poor prognosis for patients with multiple system atrophy but may be biased toward the worst cases. Future research needs to recruit more representative samples.
NEUROLOGY 1997;48: 384-393

Get full access to this article

View all available purchase options and get full access to this article.

REFERENCES

1.
Wenning GK, Ben-Shlomo Y, Magalhes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy: an analysis of 100 cases. Brain 1994;117:835-845.
2.
Magalhaes M, Wenning GK, Daniel SE, Quinn NP. Autonomic dysfunction in pathologically confirmed multiple system atrophy and idiopathic Parkinson's disease-a retrospective comparison. Acta Neurol Scand 1995;91:96-102.
3.
Schulz JB, Klockgether T, Petersen D, et al. Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with IBZM-SPECT. J Neurol Neurosurg Psychiatry 1994;57:1047-1056.
4.
Quinn N. Multiple system atrophy. In: Marsden CD, Fahn S, eds. Movement disorders 3. 1st ed. London: Butterworths and Heinemann, 1994;262-281.
5.
Wenning GK, Tison F, Ben-Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord (in press).
6.
Gilman S, Quinn NP. The relationship of multiple system atrophy to sporadic olivopontocerebellar atrophy and other forms of idiopathic late onset cerebellar atrophy. Neurology 1996;46:1197-1199.
7.
Collett D. Modelling survival data in medical research. London: Chapman and Hall, 1994:1-347.
8.
Wenning GK, Ben-Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinicopathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry 1995;58:160-166.
9.
Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
10.
Ben-Shlomo Y, Wenning G, Quinn N. Gender differences in the survival of patients with multiple system atrophy: real or artifact? New Trends Clin Neuropharmacol 1994;8:206.
11.
Dejerine J, Thomas A. L'atrophie olivo-ponto-cerebelleuse. Nouv Iconogr Salpetriere 1900;13:330-370.
12.
Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol 1960;2:511-527.
13.
Adams RD, van Bogaert L, van der Eecken H. Degenerescences nigro-striees et cerebello-nigro-striees. Psychiat Neurol 1961;142:219-259.

Information & Authors

Information

Published In

Neurology®
Volume 48Number 2February 1997
Pages: 384-393

Publication History

Published online: February 1, 1997
Published in print: February 1997

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

G. K. Wenning, MD, PhD
From the Department of Social Medicine (Dr. Ben-Shlomo), Bristol University, UK; the Department of Neurology (Dr. Wenning), University Hospital Innsbruck, Austria; the Department of Neurology (Dr. Tison), Hopital Pellegrin, Bordeaux, France; and the University Department of Neurology (Dr. Quinn), Institute of Neurology, London, UK.
Supported by the UK Parkinson's Disease Society (G.K.W.) and by a grant from Produits Roche, France (F.T.).
Presented in part at the 46th Annual Meeting of the American Academy of Neurology, Washington, DC, May 1994.
Received April 26, 1996. Accepted in final form July 16, 1996.
Address correspondence and reprint requests to Dr. Y. Ben-Shlomo, Senior Lecturer, Department of Social Medicine, University of Bristol, Canynge Hall, Whiteladies Road, Bristol BS8 2PR, UK.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Diagnostic Effectiveness of [123I]Ioflupane Single Photon Emission Computed Tomography (SPECT) in Multiple System Atrophy, Journal of Clinical Medicine, 12, 10, (3478), (2023).https://doi.org/10.3390/jcm12103478
    Crossref
  2. Sex differences in alpha-synucleinopathies: a systematic review, Frontiers in Neurology, 14, (2023).https://doi.org/10.3389/fneur.2023.1204104
    Crossref
  3. Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting, Neurology, 90, 2, (74-82), (2023)./doi/10.1212/WNL.0000000000004798
    Abstract
  4. Do published criteria improve clinical diagnostic accuracy in multiple system atrophy?, Neurology, 59, 10, (1486-1491), (2023)./doi/10.1212/01.WNL.0000028690.15001.00
    Abstract
  5. A case report and literature review of possible multiple system atrophy–parkinsonian type with cholinergic deficiency, CNS Neuroscience & Therapeutics, 29, 8, (2384-2387), (2023).https://doi.org/10.1111/cns.14243
    Crossref
  6. Exploring the mechanism of astragalus membranaceus in the treatment of multiple system atrophy based on network pharmacology and molecular docking, Medicine, 102, 5, (e32523), (2023).https://doi.org/10.1097/MD.0000000000032523
    Crossref
  7. Development and Validation of a Prognostic Model to Predict Overall Survival in Multiple System Atrophy, Movement Disorders Clinical Practice, (2023).https://doi.org/10.1002/mdc3.13822
    Crossref
  8. Epidemiology of atypical parkinsonian syndromes, Tzu Chi Medical Journal, 34, 2, (169), (2022).https://doi.org/10.4103/tcmj.tcmj_218_20
    Crossref
  9. Diagnosing Premotor Multiple System Atrophy, Neurology, 99, 11, (e1168-e1177), (2022)./doi/10.1212/WNL.0000000000200861
    Abstract
  10. Multiple system atrophy: α-Synuclein strains at the neuron-oligodendrocyte crossroad, Molecular Neurodegeneration, 17, 1, (2022).https://doi.org/10.1186/s13024-022-00579-z
    Crossref
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share